Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARIISE: Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cell Therapy in Non-ischemic Heart Failure
NCT06840275Phase 2Withdrawn
- Sponsor
- Cell to Cure
- Start
- Mar 2026
- Primary completion
- Sep 2028
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Non-ischemic heart failure (NIHF) comparing C2C_ASC110 with Placebo (2 arms). Primary endpoint: Change in left ventricular ejection fraction at 6 months. Planned start Mar 2026; status: withdrawn.
02
Drugs
C2C_ASC110
03
Conditions
Non-ischemic heart failure (NIHF)
Beyond the preview
Go deeper on NCT06840275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06840275.